Shots:
- The US FDA has granted EUA for Qiagen’s NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage Assay that will help in identifying and differentiate individuals suspected of respiratory viral infection consistent with COVID-19
- Qiagen launched the multiplex test in the EU in Nov’2020 and will now begin commercialization in the US. The company acquired NeuMoDx in Sept’2020 and the launch of this test strengthens QIAgen’s footprint in PCR and expand its COVID-19 portfolio
- The 4-plex test utilizes the high-throughput, automated testing capabilities of the NeuMoDx systems, which includes an assay menu for respiratory, blood-borne virus, transplant, and reproductive health disease areas
Click here to read full press release/ article | Ref: Qiagen | Image: Qiagen
The post Qiagen’s NeuMoDx Multiplex Test Receives the US FDA’s EUA and Expands its COVID-19 Portfolio first appeared on PharmaShots.
